This clinical trial is focused on studying the effectiveness of different durations of antibiotic treatment for a condition known as Staphylococcus aureus bacteremia. This condition occurs when the bacteria Staphylococcus aureus enters the bloodstream, potentially leading to serious infections. The study aims to compare the outcomes of patients receiving either seven or fourteen days of antibiotic treatment to determine which duration is more effective in preventing the return of the infection and ensuring patient survival.
The antibiotics being studied include several well-known medications such as Clarithromycin, Meropenem, Ceftriaxone, Cefotaxime, Piperacillin/Tazobactam, Vancomycin, Dicloxacillin, Flucloxacillin, Linezolid, Clindamycin, Levofloxacin, Moxifloxacin, Amikacin, Gentamicin, Benzylpenicillin, Cloxacillin, and Daptomycin. Some patients will receive a placebo, which is a substance with no active medication, to help compare the effects of the antibiotics. The purpose of the study is to find out if a shorter treatment period is just as effective as a longer one, which could help reduce side effects and healthcare costs.
Participants in the study will be randomly assigned to receive either seven or fourteen days of treatment. They will be monitored for 90 days after the start of the treatment to check for any signs of the infection returning or any other health issues. The study will also look at the overall health and survival of the participants during this period. This research is important for improving the treatment of Staphylococcus aureus bacteremia and ensuring patients receive the most effective care.
Denmark 
